Kids & teens (for parents) · Ohio
Studies for children and teens in Ohio
These studies only enroll people under 18. A parent or legal guardian gives permission, and children old enough to understand are asked for their own agreement (assent).
97 recruiting studiesSource: ClinicalTrials.gov, refreshed October 26, 2026How we list studies
Studies
- RecruitingPhase 3
A Study With Eptinezumab in Children and Adolescents (6 to 17 Years) With Chronic or Episodic Migraine
H. Lundbeck A/S
- Location
- Akron, OH + 13 other US sites
- Eligibility basics
- Ages 6–17
- RecruitingPhase 3
A Study of Eptinezumab in Pediatric Participants With Episodic Migraine
H. Lundbeck A/S
- Location
- Akron, OH + 8 other US sites
- Eligibility basics
- Ages 6–17
- RecruitingPhase 3
A Study of MACI in Patients Aged 10 to 17 Years With Symptomatic Chondral or Osteochondral Defects of the Knee
Vericel Corporation
- Location
- Akron, OH + 10 other US sites
- Eligibility basics
- Ages 10–17
- RecruitingPhase 3
A Study to Investigate the Efficacy and Safety of Tezepelumab Compared With Placebo in Children 5 to < 12 Years Old With Severe Asthma
AstraZeneca
- Location
- Cincinnati, OH + 18 other US sites
- Eligibility basics
- Ages 5–11
- RecruitingPhase 3
Evaluating the Efficacy and Safety of PT027 Compared With PT007 Administered As Needed in Participants 12 to < 18 Years of Age With Asthma
AstraZeneca
- Location
- Columbus, OH + 70 other US sites
- Eligibility basics
- Ages 12–17
- RecruitingPhase 1
Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability up to 6 Years of Intravenous (i.v.) Secukinumab in Pediatric Participants With Juvenile Psoriatic Arthritis (JPsA).
Novartis Pharmaceuticals
- Location
- Cincinnati, OH + 10 other US sites
- Eligibility basics
- Ages 2–17
- RecruitingPhase 1
A Clinical Study of Letermovir (MK-8228) in Children and Adolescents Who Receive a Kidney Transplant (KT) (MK-8228-077)
Merck Sharp & Dohme LLC
- Location
- Cincinnati, OH + 20 other US sites
- Eligibility basics
- Up to age 17
- RecruitingPhase 3
A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease
Eli Lilly and Company
- Location
- Dayton, OH + 10 other US sites
- Eligibility basics
- Ages 2–17
- RecruitingPhase 2/Phase 3
A Study of Enlicitide Decanoate (MK-0616, an Oral PCSK9 Inhibitor) in Children and Adolescents With Heterozygous Familial Hypercholesterolemia (MK-0616-029)
Merck Sharp & Dohme LLC
- Location
- Cincinnati, OH + 7 other US sites
- Eligibility basics
- Ages 6–17
- RecruitingPhase 2
This is a Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study of the Efficacy and Safety of 2 Weight-based Treatment Groups of Plecanatide Versus Placebo in Children and Adolescent…
Bausch Health Americas, Inc.
- Location
- Dayton, OH + 22 other US sites
- Eligibility basics
- Ages 6–17
- RecruitingPhase 2
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric Participants
Hoffmann-La Roche
- Location
- Cincinnati, OH + 8 other US sites
- Eligibility basics
- Ages 5–17
- RecruitingPhase 3
A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine
AbbVie
- Location
- Cincinnati, OH + 25 other US sites
- Eligibility basics
- Ages 6–17
- RecruitingPhase 3
A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Schizophrenia in Adolescents (EMERGENT TEEN)
Bristol-Myers Squibb
- Location
- Cincinnati, OH + 12 other US sites
- Eligibility basics
- Ages 13–17
- RecruitingPhase 4
Evaluation of SPN-812 (Viloxazine Extended-release Capsule) in Preschool-age Children With ADHD
Supernus Pharmaceuticals, Inc.
- Location
- Cincinnati, OH + 38 other US sites
- Eligibility basics
- Ages 4–5
- RecruitingPhase 4
Safety and Tolerability of Open-Labeled Iloperidone in Adolescents
Vanda Pharmaceuticals
- Location
- Cincinnati, OH + 9 other US sites
- Eligibility basics
- Ages 12–17
- RecruitingPhase 3
A Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With Asthma
GlaxoSmithKline
- Location
- Cincinnati, OH + 18 other US sites
- Eligibility basics
- Ages 12–17
- RecruitingPhase 3
An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants
AstraZeneca
- Location
- Cincinnati, OH + 18 other US sites
- Eligibility basics
- Ages 5–17
- RecruitingPhase 3
Trial Investigating the Efficacy and Safety of Weekly Lonapegsomatropin Compared to Daily Somatropin in Children and Adolescents With Short Stature or Growth Failure Due to Growth Hormone Sufficient Disorders
Ascendis Pharma A/S
- Location
- Cincinnati, OH + 21 other US sites
- Eligibility basics
- Ages 2–17
- RecruitingPhase 1
A Study to Learn About the Study Medicine Called Zavegepant (PF-07930207) in Children With a History of Migraine
Pfizer
- Location
- Cincinnati, OH + 10 other US sites
- Eligibility basics
- Ages 6–11
- RecruitingPhase 3
A Study of NNZ-2591 in Pediatric Participants With Phelan-McDermid Syndrome
Neuren Pharmaceuticals Limited
- Location
- Cincinnati, OH + 16 other US sites
- Eligibility basics
- Ages 3–12
- RecruitingPhase 3
Safety and Tolerability Trial of Lumateperone in Pediatric Patients With Schizophrenia, Bipolar Disorder or Autism Spectrum Disorder
Intra-Cellular Therapies, Inc.
- Location
- Cincinnati, OH + 46 other US sites
- Eligibility basics
- Ages 5–17
- RecruitingPhase 3
Multicenter Study of Lumateperone for the Treatment of Bipolar Depression in Pediatric Patients
Intra-Cellular Therapies, Inc.
- Location
- Cincinnati, OH + 33 other US sites
- Eligibility basics
- Ages 10–17
- RecruitingPhase 3
Multicenter Study of Lumateperone for the Treatment of Irritability Associated With Autism Spectrum Disorder in Pediatric Patients
Intra-Cellular Therapies, Inc.
- Location
- Garfield, OH + 27 other US sites
- Eligibility basics
- Ages 5–17
- RecruitingPhase 3
A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder
Janssen Research & Development, LLC
- Location
- Cincinnati, OH + 9 other US sites
- Eligibility basics
- Ages 12–17